Physician profile
Malik C Spady
NPI 1649259789
$159,818.29
in general payments reported to CMS, 2019-2025
25 companies · $7,181 in 2025
The $7,181 reported for 2025 was more than what 88% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $39K · 2020: $12K · 2021: $17K · 2022: $27K · 2023: $25K · 2024: $33K · 2025: $7,181.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $50K · Food and Beverage: $8,468 · Travel and Lodging: $7,019 · Education: $8.23.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $49,631.00 |
| Food and Beverage | $8,468.03 |
| Travel and Lodging | $7,018.73 |
| Education | $8.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $66,109.72 | 2020-2025 | Acthar |
| Mallinckrodt Enterprises LLC | $27,278.66 | 2019 | |
| Janssen Biotech, INC. | $25,638.28 | 2021-2025 | Tremfya, Simponi Aria |
| Novartis Pharmaceuticals Corporation | $19,805.91 | 2019-2025 | |
| Janssen Scientific Affairs, LLC | $5,973.44 | 2022-2023 | Tremfya, Stelara, Simponi Aria |
| Horizon Therapeutics Plc | $5,427.62 | 2019-2022 | |
| Abbvie INC. | $2,550.70 | 2019-2025 | Rinvoq, Skyrizi |
| Amgen INC. | $1,808.28 | 2019-2025 | Enbrel, Tavneos, Otezla |
| Ucb, INC. | $1,100.47 | 2019-2025 | Cimzia, Bimzelx |
| Pfizer INC. | $1,044.37 | 2019-2024 | |
| Glaxosmithkline, LLC. | $803.38 | 2019-2025 | Benlysta |
| Lilly USA, LLC | $536.47 | 2019-2024 | Taltz, Olumiant |
| Ani Pharmaceuticals, INC. | $494.49 | 2022-2024 | Purified Cortrophin Gel |
| Aurinia Pharma U.S., INC. | $445.39 | 2021-2025 | Lupkynis |
| E.R. Squibb & Sons, L.L.C. | $241.33 | 2019-2025 | Orencia |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $232.73 | 2019-2020 | |
| Sandoz INC. | $90.73 | 2023 | Hyrimoz |
| Alexion Pharmaceuticals, INC. | $55.10 | 2022-2024 | Strensiq |
| Idorsia Pharmaceuticals US INC | $46.71 | 2022-2023 | Quviviq |
| Kiniksa Pharmaceuticals International, Plc | $40.87 | 2024 | Arcalyst |
| Astrazeneca Pharmaceuticals LP | $22.28 | 2023 | Saphnelo |
| Radius Health, INC. | $19.71 | 2024 | |
| Genentech USA, INC. | $18.17 | 2025 | Gazyva |
| Takeda Pharmaceuticals U.S.A., INC. | $18.06 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $15.42 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Malik Spady listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.